Movement disorders: insights into mechanisms and hopes for treatment

The Lancet Neurology

Volumn 8, Issue 1, 2009, Pages 8-10

  Wider, Christian ^a   Wszolek, Zbigniew K ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BROMOCRIPTINE; GLUCOSE TRANSPORTER 1; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; PROTEIN KINASE; PROTEIN KINASE R; SELEGILINE; TAU PROTEIN;

ARTICLE; DYSTONIA; FETAL STEM CELL; GENE MUTATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; STEM CELL TRANSPLANTATION;

EID: 57149109123     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70273-4     Document Type: Note

References (10)

1. Ross O.A., Wu Y.R., Lee M.C., et al. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol 64 (2008) 88-92
2. Freed C.R., Greene P.E., Breeze R.E., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 (2001) 710-719
3. Olanow C.W., Goetz C.G., Kordower J.H., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 (2003) 403-414
4. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., and Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14 (2008) 504-506
5. Li J.Y., Englund E., Holton J.L., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14 (2008) 501-503
6. Mendez I., Vinuela A., Astradsson A., et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 14 (2008) 507-509
7. Albin R.L., and Frey K.A. Initial agonist treatment of Parkinson disease: a critique. Neurology 60 (2003) 390-394
8. Katzenschlager R., Head J., Schrag A., Ben-Shlomo Y., Evans A., and Lees A.J. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 71 (2008) 474-480
9. Camargos S., Scholz S., Simon-Sanchez J., et al. DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol 7 (2008) 207-215
10. Weber Y.G., Storch A., Wuttke T.V., et al. GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Invest 118 (2008) 2157-2168